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Cystic ﬁbrosis (CF) is a common autosomal recessive disorder in Caucasian populations with respiratory,
gastrointestinal and endocrine manifestations. Thanks to recent advances in medical therapies and
infection control, life expectancy of a patient with CF has signiﬁcantly increased from less than 5 years in
the mid-1900s to almost 50 years nowadays. However, as CF patients are living longer, multimorbidity
and Hyperpharmacotherapy are becoming more common. This case illustrates a cascade of problems that
ensued from medication side-effects, highlighting the increasing challenge of managing an ageing CF
population.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cystic ﬁbrosis (CF) is a common autosomal recessive disorder in
Caucasian populations [1]. It is caused by mutations in cystic
ﬁbrosis transmembrane conductance regulator (CFTR) gene giving
rise to respiratory, gastrointestinal and endocrine manifestations
[1]. Survival rates for patients with CF have been increasing with
continued developments of CF speciﬁc therapies. This trend is likely
to increase in decades to come. Currently themedian survival in the
UK is 43.5 years and it is estimated that a child born today with CF
will live into their ﬁfties [2,3]. As patients are ageing they accu-
mulate more complications and comorbidities and these go hand in
hand with an increasing treatment burden. Here the authors pre-
sent the ﬁrst report of an atypical hip fracture in a CF patient.
2. Ethical approval
No identiﬁable patient information are presented. Patient con-
sent was sought and documented in clinical notes.
3. Case description
The case of a 54-year-old male whowas a late diagnosis of cystic
ﬁbrosis (DF508/D1152H) is presented. He was diagnosed at the ageckers).
Ltd. This is an open access article uof 48 after 8 years of poorly controlled allergic bronchopulmonary
aspergillosis (ABPA) necessitating long term prednisolone therapy.
Four years prior to his diagnosis of CF he sustained several rib
fractures during a coughing episode. At this juncture his bone
density (DXA) scan T scores were T score Total Hip 0.6, T score
Lumbar spine (LS) 1.5 and he was maintained on Calchichew D3
Forte, Prednisolone 10 mg and Itraconazole. His serum calcium,
vitamin D, Testosterone, Thyroid function and parathyroid hor-
mone were all normal. He was started on Alendronic acid 70 mg
once weekly. He remained on this treatment for ﬁve years during
which he had annual DXA scans and was noted that his Bone
Mineral Densities (BMDs) were improving (T score hip 0.4, LS
1.2). He was given a bisphosphonate holiday for one year but a
mild drop of his BMD (T score LS 1.3) whilst on long term pred-
nisolone (10 mg) for ABPA prompted the initiation of Ibandronate
150 mg once monthly which he continued for four years.
During this period he accrued several co morbidities including
pancreatic insufﬁciency, impaired oral glucose tolerance, hyper-
tension, hypercholesterolaemia, obstructive sleep apnoea, elevated
body mass index (BMI) of 30 kg/m2 and chronic methicillin resis-
tant staphylococcus aureus (MRSA) colonisation.
His forced expiratory volume in 1 s percent predicted (FEV1%)
dropped to 30%, his quality of life deteriorated and exacerbation
frequency increased with two admissions with acute type two
respiratory failure necessitating non-invasive ventilation. He was
referred for consideration of lung transplantation and concerns
were raised regarding MRSA colonisation (repeat eradicationnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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instated).
During this period he presented with a respiratory exacerbation
and he was commenced on Ciproﬂoxacin 1g twice daily orally.
Unfortunately he developed Achilles tendonitis and the Ciproﬂox-
acin was stopped but due to weakness he tripped whilst walking
down a step and sustained a fracture at the base of his right 5th
metatarsal bone.
Ibandronic acid was stopped since the fracture had not healed
after 20 weeks and he was given a non-weight bearing-orthotic
shoe and crutches. Fractures of the 5th metatarsal would usually be
expected to heal in around six to eight weeks.
As there was poor callus formation and ongoing pain over a
period of several months he was commenced on daily subcutane-
ous Teriparatide (recombinant human 1e34 parathyroid hormone)
to stimulate bone formation.
There was some bone healing and eight months after the frac-
ture he began weight bearing.
Four months later, he complained of pain in his left groin after
twisting when carrying his ambulatory oxygen through a narrow
doorway. Examination was unremarkable and an XR was per-
formed (Fig. 1).
The appearances were highly suggestive of an atypical fracture
meeting all the major criteria (between lesser trochanter and
supracondylar ﬂare, minimal trauma, transverse or short oblique
conﬁguration, non-comminuted, incomplete fracture involving
only the lateral cortex)[4]. The fracture necessitated internal ﬁxa-
tion performed under general anaesthetic. The operative bone bi-
opsy revealed degenerative change and markers of bone turnover,
urinary N Telopeptide and P1NP, were within quoted normal range.
[Urinary N Telopeptide 34 BCE/Mmol, P1NP 70ug/l (normal range
20e76)]. Renal function and Total 25OH Vit D were normal. [vit
d ¼ 95.4 nmol/l, egfr >90].
Subsequently he became further deconditioned, his BMI
increased to 33 kg/m2 and motivation remained low; he is now no
longer a candidate for consideration of bilateral sequential lung
transplantation.
4. Discussion
Multimorbidity is deﬁned as the co-occurrence of multiple
chronic or acute diseases and medical conditions within one per-
son. This is becoming more common as CF patients live longer. For
instance, CF related low bone mineral density (CFRLBMD) occurs inFig. 1. Atypical fracture left femur.34% of CF patients [4] with a multifactorial aetiology. Studies have
revealed that 14% of CF patients have evidence of vertebral fractures
and 20% non-vertebral fractures [5]. Guidelines on the manage-
ment of CFRLBMD advocate a combination of both preventive and
treatment strategies [6]. However, in following guidelines for pa-
tients with multimorbidity there is a danger of not considering the
cumulative impact of treatment recommendations as most guide-
lines were derived from research that automatically excluded pa-
tients with multiple co-morbidities.
The subject of this reportwas amiddle aged patientwith CFwith
high multimorbidity and on 17 different medications. Although the
term ‘Polypharmacy’ has been used for decades to describe such a
situation, a clear deﬁnition is lacking. A recent review of the litera-
ture revealed 24 different deﬁnitions of polypharmacy with ‘a
medication not matching diagnosis’ as the most commonly cited
deﬁnition [7]. It is now recommended to use less ambiguous ter-
minology such as hyperpharmacotherapy or multiple medication
use. The presence of drug related problems (DRPs) has been shown
to increase approximately linearly with the number of drugs used,
for the range of one to more than 11 drugs [8].
Ciproﬂoxacin, a second generation ﬂuoroquinolone antibiotic
(FA), is commonly used to treat a respiratory exacerbation in CF
patients. The incidence of Fluoroqinolone induced tendinopathy
(FIT) in healthy population is unclear but estimated to ranges be-
tween 0.14% and 0.4%. However, higher risks were observed with
advanced age, obesity, concurrent use of glucocorticoids, diabetes
mellitus, chronic renal disease, chronic lung disease and partici-
pation in sports activities [9]. Unfortunately the subject of this
report had multiple risk factors for developing FA induced ten-
dinopathy. His achilles tendonitis resulting in weakness and sub-
sequent fall and fracture at the base of his 5th metatarsal bone. The
consequences of this were further deconditioning and inability to
reduce BMI.
He was also on bisphosphonates, a class of drugs that inhibit
bone resorption. Bisphosphonates are themainstay of management
of CFRLBMD and have been shown to increase BMD in CF patients,
but there is currently insufﬁcient data to demonstrate effect on
fracture incidence. Current European Cystic Fibrosis bone miner-
alisation guidelines [3] recommend the use of bisphosphonates in
CF patients with evidence of significant bone loss, low trauma
fracture or continuous systemic oral glucocorticoids for more three
months with a BMD less than T/Z score of 1.5.
Side effects include osteonecrosis of the jaw, oesophageal ul-
ceration, bone pain and ﬂu-like symptoms. Atypical fractures are
rare but have been reported more with long term treatment thus
suggesting re-evaluation of use after ﬁve years and consideration of
‘drug holidays’ in selected patients [10]. Another undesirable side
effect of long-term systemic bisphosphonate administration is
delayed healing of fractures due to delayed maturation and
remodelling of callus. This delay can persist even after bisphosph-
onate administration is stopped. Despite these uncommon but
signiﬁcant adverse events, a local study showed that 41% (n¼ 16) of
patients on long-term bisphosphonate (n ¼ 39) had received
treatment for more than ﬁve years without break.
The consequences of this poorly healing metatarsal fracture
followed by an atypical hip fracture for this patient were grave. The
deconditioning and weight gain following the metatarsal fracture
had a signiﬁcant psychological and emotional impact on him and
the hip fracture posed a major perioperative risk.
This rare complication of bisphosphonates use has not been
previously reported in a patient with CF. It highlights the impor-
tance of weighing up all possible risks against beneﬁts when pre-
scribing bisphosphonates. Further research into the optimum
duration of treatments is vital in order to aid decision making
process.
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This case illustrates a cascade of problems that ensued from
medication side-effects; starting from the glucocorticoid induced
low BMD to the ciproﬂoxacin causing Achilles' tendonitis and
subsequent metatarsal fracture and ﬁnally an atypical fracture
related to bisphosphonate use. It serves as a potent reminder of the
increasing challenges of hyperpharmacotherapy in an ageing CF
population with multimorbidity.
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